19:04 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Detailed data for Pfizer, Lilly anti-NGF mAb highlighted at ACR/ARHP

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) reported detailed efficacy data from the Phase III A4091056 trial evaluating tanezumab compared with placebo to treat osteoarthritis pain. The data showed tanezumab led to...
23:25 , Oct 24, 2018 |  BC Extra  |  Clinical News

Detailed data for Pfizer, Lilly anti-NGF mAb highlighted at ACR/ARHP

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) reported detailed efficacy data late Tuesday from the Phase III A4091056 trial evaluating tanezumab compared with placebo to treat osteoarthritis pain. The data showed tanezumab...
01:55 , Oct 13, 2018 |  BioCentury  |  Product Development

Bourla’s breadcrumbs to value

Incoming CEO Albert Bourla has spent only a few of his 25 years at Pfizer Inc. in the pharma’s innovative drugs business, but there are signs he already has laid the groundwork for innovating how...
21:45 , Oct 1, 2018 |  BC Extra  |  Company News

Pfizer COO Bourla to succeed Read as CEO

Pfizer Inc. (NYSE:PFE) named an insider, COO Albert Bourla, to succeed Ian Read as CEO on Jan. 1. During Read’s eight-year tenure, he reshaped Pfizer into a slimmer, three-part organization and helped it navigate key...
18:23 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

FDA approves CV label update for Pfizer's Celebrex

FDA approved a label supplement for Celebrex celecoxib from Pfizer Inc. (NYSE:PFE) to include data from a postmarketing cardiovascular outcomes trial showing that the lowest approved dose of Celebrex had similar CV safety to that...
15:20 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Muscular dystrophy Mouse studies suggest that COX-2 inhibition could help treat Duchenne muscular dystrophy (DMD). In a mouse model of DMD, the COX-2 inhibitor Celebrex celecoxib decreased immune cell infiltration in tibialis anterior muscle...
19:56 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

FDA panel affirms safety of Pfizer's Celebrex

FDA's Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 15-5 that the Phase IV CV outcomes PRECISION trial showed that Celebrex celecoxib from Pfizer Inc. (NYSE:PFE) had comparable cardiovascular safety to...
20:48 , Apr 25, 2018 |  BC Extra  |  Company News

FDA panel affirms safety of Pfizer's Celebrex

FDA's Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 15-5 that the Phase IV CV outcomes PRECISION trial showed that Celebrex celecoxib from Pfizer Inc. (NYSE:PFE) had comparable cardiovascular safety to...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
18:21 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Epilepsy Mouse studies suggest inhibiting COX-2 could help treat autosomal dominant lateral temporal lobe epilepsy (ADLTE), which is caused by LGI1 mutations. In cortex samples from a LGI1-knockout mouse model of ADLTE, levels of...